Cited by 229Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisFerroptosis and cancer prognosis

The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.

Biomarkers for immunotherapy of hepatocellular carcinoma

Greten, Tim F., Villanueva, Augusto, Korangy, Firouzeh, Ruf, Benjamin, Yarchoan, Mark, Ma, Lichun, Ruppin, Eytan, Wang, Xin W.·2023·Nature Reviews Clinical Oncology

DOI 10.1038/s41571-023-00816-4

Open this paper in CoChat — free account

Abstract

Immune-checkpoint inhibitors (ICIs) are now widely used for the treatment of patients with advanced-stage hepatocellular carcinoma (HCC). Two different ICI-containing regimens, atezolizumab plus bevacizumab and tremelimumab plus durvalumab, are now approved standard-of-care first-line therapies in this setting. However, and despite substantial improvements in survival outcomes relative to sorafenib, most patients with advanced-stage HCC do not derive durable benefit from these regimens. Advances in genome sequencing including the use of single-cell RNA sequencing (both of tumour material and blood samples), as well as immune cell identification strategies and other techniques such as radiomics and analysis of the microbiota, have created considerable potential for the identification of novel predictive biomarkers enabling the accurate selection of patients who are most likely to derive benefit from ICIs. In this Review, we summarize data on the immunology of HCC and the outcomes in patients receiving ICIs for the treatment of this disease. We then provide an overview of current biomarker use and developments in the past 5 years, including gene signatures, circulating tumour cells, high-dimensional flow cytometry, single-cell RNA sequencing as well as approaches involving the microbiome, radiomics and clinical markers. Novel concepts for further biomarker development in HCC are then discussed including biomarker-driven trials, spatial transcriptomics and integrated 'big data' analysis approaches. These concepts all have the potential to better identify patients who are most likely to benefit from ICIs and to promote the development of new treatment approaches.

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00816-4

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer statistics, 2023
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,394
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Hepatocellular carcinoma
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citation
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974

Show all 205 references

Research works printed but not linked: 2

Hoang, D.-T. et al. Synthetic lethality-based prediction of cancer treatment response from histopathology images. Cell 3, 2487–2502.e13 (2023).
Cao, Y. et al. Predicting tumor immune microenvironment and checkpoint therapy response of head & neck cancer patients from blood immune single-cell transcriptomics. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2023.01.17.524455v1 (2023). · DOI

Sorted by citations

Items 101–200 of 229

The Dichotomous Role of Tertiary Lymphoid Structures in Hepatocellular Carcinoma: From Spatial Location to Clinical Implications
Xu, J., Cheng, Y., Feng, Y., & Wang, Y. (2025) · Immunological Investigations · doi:10.1080/08820139.2025.2553774 · Cited by 4
A prognostic and immune related risk model based on zinc homeostasis in hepatocellular carcinoma
Shi, Y., Ye, R., Gao, Y., Xia, F., & Yu, X. (2024) · iScience · doi:10.1016/j.isci.2024.109389 · Cited by 4
Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma
Huang, Y., & Yu, W. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0375 · Cited by 5
Circulating Biomarkers Predict Immunotherapeutic Response in Hepatocellular Carcinoma Using a Machine Learning Method
Dai, Z., Chen, C., Zhou, Z., Zhou, M., Xie, Z., Liu, Z., Liu, S., Chen, Y., Li, J., Liu, B., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s474593 · Cited by 4
Comprehensive multi-omics analysis of bile acid metabolism in hepatocellular carcinoma: implications for prognosis, immune microenvironment, and therapeutic resistance
Ma, J., Cheng, M. Y., Jin, L., Wang, Y., Feng, Z., Shen, Y., Zhu, Y., & Peng, Q. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03963-5 · Cited by 4
Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential
Cheng, C. C. Y., Cheung, M. F., Lee, A. Y., Wu, Q., Chow, S. H.-C., Ang, J. Y. J., Riquelme Medina, I., Lo, G., Wu, H., Yang, W., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09154-w · Cited by 3
Unraveling the immune-activated tumor microenvironment correlated with clinical response to atezolizumab plus bevacizumab in advanced HCC
Lim, J., Goh, M. J., Song, B. G., Sinn, D. H., Kang, W., Gwak, G., Choi, M. S., Lee, J. H., Cha, D. I., Gu, K., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101304 · Cited by 3
High Fibroblast Activation Protein Expression in Hepatocellular Carcinoma: CT Imaging Features and Histological Characteristics
Wang, T.-C., Huang, W., Li, S.-X., Li, J., Zhou, P., Wang, L., Wei, N., Cai, W., Hu, J., & Xiao, Y. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.04.016 · Cited by 4
Intrapatient Variation in Response to Systemic Therapy in Advanced Hepatocellular Carcinoma
Johnson, P. J., & Boswell, E. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00015 · Cited by 3
TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8+ T cells via lysosome-dependent degradation of TCF-1
Jiang, P., Chen, D., Chen, J., Wu, J., Zhong, Y., Huang, S., Mu, X., Lu, X., & Wang, X. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.006 · Cited by 3
Self-citation
Mineralized Supramolecular Microspheres with Immunoregulating Functions for Transarterial Chemoembolization Immunotherapy of Hepatocellular Carcinoma
Zhang, M., Wang, Y., Tang, X., Zhang, W., Mao, Z., Yuan, Y. L., Yang, X., Yu, G., & Chen, X. S. (2025) · Small Methods · doi:10.1002/smtd.202500857 · Cited by 3
Predicting tumor micronecrosis in hepatocellular carcinoma using pretreatment contrast-enhanced CT radiomics model: a multi-center study
Wang, Y., Huang, C., Ye, M., Chen, C., Xia, T., Tian, Y., Xu, Y., Ding, H., Zhang, Y., Gao, Y., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01133-y · Cited by 3
Regulated necrosis at the crossroads of liver inflammation and cancer development
Vucur, M., Kondylis, V., Brož, P., & Luedde, T. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01147-8 · Cited by 6
DNASE1L3 regulates macrophage polarization through the NLRP3-GSDMD signaling pathway affecting hepatocellular carcinoma progression
Liu, Y., Zhang, B., Meng, Z., Lei, L., Song, Y., Lan, J., Li, B., Ouyang, C., Yuan, S., Liu, P., et al. (2025) · Molecular Biology of the Cell · doi:10.1091/mbc.e25-05-0265 · Cited by 3
Dihydroartemisinin promotes ABCG5/G8-mediated cholesterol efflux to potentiate anti-PD-1 therapy through YAP1-TEAD1 complex disruption in hepatocellular carcinoma
Gao, Y., Gong, Y., Du, Z., Zhang, W., Lai, L., Lan, M., Jia, Z., Song, X., Xiong, Y., Gong, Y., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158584 · Cited by 3
Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives
Li, C. C., Liu, M., Lee, H.-P., Wu, W., & Ma, L. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1787152 · Cited by 3
Self-citation
Advances in the study of the mechanism of action of miR‑22 in liver lesions (Review)
Wang, M., Wang, X., Wang, Y., Gai, Y., Ye, J., Xu, X., & You, X. (2024) · Oncology Letters · doi:10.3892/ol.2024.14674 · Cited by 3
Self-citation
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023
Bao, Y., Mo, Z., Wang, S., Long, J., Zhang, H., Xu, Y., Jiang, H., Qian, T., & Zeng, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1475062 · Cited by 3
Immunotherapy in Gastrointestinal Cancers: Current Insights
Jiang, X., Zhan, Y., Yang, D., & Bao, L. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497836 · Cited by 3
Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Cui, M., Jiang, L., Yang, W., & Zhang, W. (2024) · Journal of Visualized Experiments · doi:10.3791/66599 · Cited by 3
From Genesis to Old Age: Exploring the Immune System One Cell at a Time with Flow Cytometry
Larbi, A. (2024) · Biomedicines · doi:10.3390/biomedicines12071469 · Cited by 4
Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI
Kang, J. G., Han, K., Chung, T., & Rhee, H. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111772 · Cited by 3
Liver Cancer Neuroscience: Regulating Liver Tumors via Selective Hepatic Vagotomy
Bauer, K. C., Ghabra, S., Ma, C., Chedester, L., & Greten, T. F. (2024) · Methods and Protocols · doi:10.3390/mps7060099 · Cited by 3
Self-citation
Machine learning and multi-omics characterization of SLC2A1 as a prognostic factor in hepatocellular carcinoma
Xu, K., Zhang, H., Dai, H., & Mao, W. (2024) · Gene · doi:10.1016/j.gene.2024.149178 · Cited by 3
Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression
He, J., Guo, J., Liu, S., Li, H., Ma, Y., Ma, S., Hu, Z., Zhao, W., Tan, M., Liu, W. Y., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111665 · Cited by 3
Immunotherapy for hepatocellular carcinoma
Guan, Z., Zhu, G., Liu, W., & Shi, Y. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00040-4 · Cited by 3
A bibliometric and visual analysis based on immune checkpoint inhibitors for hepatocellular carcinoma: 2014 – 2024
Liu, G., Guo, R., & Xu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1520055 · Cited by 2
The molecular characteristics of DNA damage and repair related to P53 mutation for predicting the recurrence and immunotherapy response in hepatocellular carcinoma
Ma, J., Tang, D., Cui, G., Zhang, X., Wang, X., Li, Y., Hu, E., Zhou, X. H., Liu, H., Peng, Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-99853-5 · Cited by 2
Self-citation
Up-regulation of blood-circulating TIM-4-expressing monocytes and potential diagnostic biomarker sTIM-4 in primary liver cancer
Yang, Y., Wei, Y., Zhao, Y., Ye, C., Zeng, D. L., Zhou, X., Xie, M., Chen, X., Qing, J., & Chen, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-14361-w · Cited by 2
Post-translational acylation modulates immunosuppression and immunotherapy efficacy in hepatocellular carcinoma
Li, Y., Bai, S., Hu, J., Li, H., Chen, H., Zhao, J., Qian, H., Tang, Z., & Feng, Y. (2025) · Genes and Immunity · doi:10.1038/s41435-025-00362-2 · Cited by 2
Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy
Zhang, S., Wang, H., Cho, Y., da Rocha, H. L., Wong, W., Yarchoan, M. M., Jaffee, E. M., Ho, W. J., Kagohara, L. T., Fertig, E. J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525799123 · Cited by 2
Self-citation
Expert consensus on multidisciplinary collaboration in perioperative immunotherapy for hepatocellular carcinoma (2025 edition)
Ding, Z., Yuan, C., Zhu, Y., Wu, H., Dai, H., Wang, J., Sun, M., Yu, D., Xia, F., Wang, K., et al. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000122 · Cited by 2
Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8 + T‐Cell‐Driven Cancer Cell Pyroptosis
Zhu, K., Zhang, F., Qin, C., Song, Z., Yang, C., Lin, S., Yu, X., Wu, W., Liu, C., Liu, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202512845 · Cited by 2
Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy
Tan, J., Fang, J., Luo, W., Chen, X., Liang, Y., Huang, Z., Tan, S., Ren, M., Xu, X., Zhang, W., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s544668 · Cited by 2
Integrated multi-omics analysis reveals that MARCKS reprograms the immunosuppressive microenvironment to drive hepatocellular carcinoma progression
Qin, H., Lu, Q., Hu, B., Zhou, X., Lan, C., Lu, H., Gao, D., Qin, C., Peng, K., Wei, Y., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01372-7 · Cited by 2
Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma
Cui, Y., Wang, L., Li, X., Wang, K., Wang, H., Bao, Q., Zhu, H., Gu, X., Xing, Q., Jin, K.-M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1782008 · Cited by 2
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma
Nishio, A., Kodama, T., Daiku, K., Maesaka, K., Tanaka, S., Nozaki, Y., Kurahashi, T., Matsumoto, K., Nawa, T., Tawara, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013648 · Cited by 2
Pan-cancer analysis of single-cell profiles with polygenic signals reveals genetic influences on tumor immunity across cancers
Deng, C., Ka, L., Ma, Y., Li, J., Li, Y. Z., Su, M., Zhou, Y., Zhang, Y., Su, J., & Zhang, Y. (2026) · Communications Biology · doi:10.1038/s42003-026-10158-3 · Cited by 2
Toward oral nanomaterial-based drug delivery systems for hepatocellular carcinoma therapy: evidence mapping, route-specific validation, and translational challenges
Fu, Y., Ge, Y., Yi, S., Peng, Q., Jiang, H., & Zhou, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1854700 · Cited by 2
Dendritic Cell-Related Gene Signatures in Hepatocellular Carcinoma: An Analysis for Prognosis and Therapy Efficacy Evaluation
Huang, H., Peng, S., Wei, Y., Lan, C., Qin, W., Liao, X., Yang, C., Zhu, G., Zhou, X., & Peng, T. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s481338 · Cited by 2
Stratifying hepatocellular carcinoma based on immunophenotypes for immunotherapy response and prognosis
Liu, Y., Ji, H., Wu, L., Wang, X.-X., Yang, Y., Zhang, Q., & Zhang, H. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200890 · Cited by 2
Self-citation
Identification of a novel immunogenic cell death-related classifier to predict prognosis and optimize precision treatment in hepatocellular carcinoma
Zhang, D., Lu, B., Ma, Q., Xu, W. B., Zhang, Q., Xiao, Z., Li, Y., Ren, C., & Wang, A. (2025) · Heliyon · doi:10.1016/j.heliyon.2024.e41380 · Cited by 2
Complete remission in an advanced hepatocellular carcinoma patient with AXIN1 mutation after systemic therapy: A case report
Ran, Y., Huang, X., Che, X., & Chen, D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42010 · Cited by 2
Aptamer‐Signatured Nanoparticle Protein Corona for Size‐Dependent Fluorescent Barcoding Diagnosis
Sun, Y., Fan, J., Zong, Y., Jin, B., Yao, W., Wang, Z., Fu, T., Fang, L., Liu, Y., & Tan, W. (2025) · Small · doi:10.1002/smll.202410434 · Cited by 2
Evaluating Predictors of Quality in Liver NK Cells Among Deceased Donors
Imaoka, Y., Ohira, M., Nakayama, T., Akabane, M., Tajima, T., Yokota, S., Krams, S. M., Martinez, O. M., Esquivel, C. O., Sasaki, K., et al. (2024) · Cell Transplantation · doi:10.1177/09636897241283289 · Cited by 2
Computed tomography radiomics combined with clinical parameters for hepatocellular carcinoma differentiation: a machine learning investigation
Ma, S., Zhu, Y., Pu, C., Li, J., & bin zhong (2025) · Polish Journal of Radiology · doi:10.5114/pjr/200631 · Cited by 1
FOXK1-induced upregulation of NXPH4 predicts poor prognosis and promotes hepatocellular carcinoma progression via PI3K/Akt pathway
Wang, Y. (2025) · American Journal of Cancer Research · doi:10.62347/zlos1416 · Cited by 1
Clinical Significance of CD90(+) Circulating Tumor Cells as Dynamic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab and Lenvatinib
Nosaka, T., Murata, Y., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Ohtani, M., & Nakamoto, Y. (2025) · Cancers · doi:10.3390/cancers17172829 · Cited by 1
Molecular subtyping and therapeutic prediction of hepatocellular carcinoma based on exosome proteomics
Mao, M., Zhang, Z., Zhang, Y., Zuo, T., Chang, L., Lu, S., Zhang, Y., Zhang, Z., & Xu, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147983 · Cited by 1
Impact of Cytokeratin 19 Expression on the Outcomes of Unresectable Hepatocellular Carcinoma Treated with Targeted Therapy and Immunotherapy: A Propensity Score Matched Analysis
Liu, J., Yuan, T., Lv, X., Tan, G., Lin, X., & Zhiyong, H. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s555248 · Cited by 1
Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma
Li, Y., Liu, Z., Qian, Y., Wang, K., Gu, Y., Chen, Y., Jiang, H., Cheng, S., & Jiang, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334099 · Cited by 1
Symptom experiences and coping strategies of liver cancer patients receiving targeted therapy combined with immunotherapy in China: A qualitative study
Han, B., Li, S., Zhu, S., WenJuan, X., Huang, L., Cai, S., & Cao, C. (2025) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2025.103048 · Cited by 1
Peripheral inflammatory indices and outcomes under PD-1/PD-L1–based regimens in HCC: an exploratory single-center retrospective analysis
Qiao, R., Zhu, W., Wang, L., Hei, Y., Wang, X., Yang, R., Kong, S., Qin, H.-Y., & Chen, Y. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00218-9 · Cited by 1
Self-citation
Hot−yet−suppressed under PD−1 blockade: an RMP–NRF2–PD−L1 axis associated with a reduced proportional response in hepatocellular carcinoma
Zuo, M., Li, H., Chen, N., Guo, Z., & Wan, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1737569 · Cited by 1
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Sato, Y., Kodama, T., Maesaka, K., Kai, M., Murai, K., Tahata, Y., Saito, Y., Nakabori, T., Ohkawa, K., Tanaka, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013384 · Cited by 1
Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study
Shi, F., Peng, Z., Lian, S., Mai, Q., Xia, D., Li, Q., Wang, M., Chen, S., Mei, J., Han, G., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02406-4 · Cited by 1
Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies
Wang, Z., Wu, J., Li, Q., & Wen, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1804366 · Cited by 1
Neutrophil polarization landscapes in HCC: From immunosuppressive niches to antitumor immunity resuscitation
Sun, J., Yang, F., Li, Y., Li, S., & Song, J. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218527 · Cited by 2
Immunotherapy and Hepatocellular Carcinoma: From Tumor-Immune Cell Interactions to Rational Therapeutic Strategies
Yuza, K., & Pawlik, T. M. (2026) · Cells · doi:10.3390/cells15121097 · Cited by 1
Correlation Between Low Cytoplasmic Expression of XBP1 and the Likelihood of Surviving Hepatocellular Carcinoma
Hsu, H., Lin, Y.-M., Hsing, M., Yeh, K.-T., Lu, J., & Yang, S.-F. (2024) · In Vivo · doi:10.21873/invivo.13571 · Cited by 1
Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy
Silveira, M. A. D., Rodrigues, R. R., & Trinchieri, G. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2024.10.005 · Cited by 3
Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatmentsPreprint
Delamarre, A., Decraecker, M., Blanc, J., Di-Tommaso, S., Dourthe, C., Dupuy, J., Moreau, M., Allain, N., Mahouche, I., Giraud, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.03.631224 · Cited by 1
Establishment of a prognostic signature for pancreatic cancer using immune checkpoint-related lncRNAsPreprint
Yang, Y., Ma, X., Zhou, C., Xu, N., Ding, D., Huo, J., Ma, Z., Zhou, L., Cui, P., & Liu, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4057958/v1
Preoperative MRI features for predicting response to postoperative adjuvant anti-PD-1 therapy in hepatocellular carcinomaPreprint
Peng, Z., He, X., Zhan, J., Sun, Y., & Hu, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4593371/v1
Identification of Hub Genes and CDK1-Targeting Therapeutics in Hepatocellular Carcinoma: Bioinformatics and Simulation StudyPreprint
Romero, R. C., & Toledo, C. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.617319
Gut Microbiome: Associations with Liver and Colon Cancer
Sharma, S. P., & Suk, K. T. (2024) · Springer eBooks · doi:10.1007/978-981-96-0297-1_11
Radiomics in Hepatology
Kim, T.-H., Gian, R. K., Akın, O., & Schwartz, L. H. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.004
Multiparametric MRI–Based Machine Learning Radiomics Prognostic Models for Multifocal Hepatocellular Carcinoma Beyond Milan Criteria: A Retrospective Study
Liang, X., Wu, F., Zheng, X., Xiao, Y., Yang, C., & Zeng, M. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s528391
Present and future of systemic therapy for early and intermediate stages of hepatocellular carcinoma
Mateu, C. A., & Ponce, J. J. U. (2025) · Revisiones en cáncer · doi:10.20960/revcancer.00104
EGFL9 regulates the growth and metastasis of hepatocellular carcinoma through EGFR/PI3K/AKT signaling pathway and amino acid modulation
Li, Z., Feng, J., Zhao, L., Wang, L., Shen, X., Yuan, W., Wang, B., & Wu, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03531-x
FCGR2A defines prognostic immune subtypes and drives tumor progression in hepatocellular carcinoma
Zhong, D., Liang, Y., Yan, H., Chen, X., Chen, Y., Ma, S., Su, Y., Wang, F., Chen, X., Yang, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641420
Tumormikromilieu des hepatozellulären Karzinoms – Schlüssel zur Therapiestratifizierung von Lebertumoren
Schlaak, A. E., Thimme, R., & Bengsch, B. (2025) · Die Onkologie · doi:10.1007/s00761-025-01854-6
Research Progress of TACE Combined with Immunotherapy and Anti-Vascular Triple Therapy in Unresectable Hepatocellular Carcinoma
Guo, Y., & Xu, W. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.1311023
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma
Karunakaran, S., Ghanta, M. K., Cheetiyar, A. L., Bhaskar, L. V., & Nagaraju, G. P. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104556 · Cited by 1
LASSO-empowered nomogram integrating nutritional-inflammatory-tumor characteristics predicts immunotherapy outcomes in advanced HCC: Large retrospective cohort
Hu, S., Xu, M., Li, S., Chen, W., & Peng, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626940
Interaction between HBsAg response and the prognosis of patients with HBV-associated HCC receiving anti-PD-1/PD-L1
Zhang, X., Xu, Q., Ma, Q.-X., & Yang, Y. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12312-4
Mitochondrial-associated PCD signature defines immune landscape, therapeutic sensitivity, and prognosis in hepatocellular carcinoma
Luo, X.-Q., Cao, Y.-M., Peng, Y., Dong, J., Chen, Z.-Y., Xiao, L., Wang, W., & Ai, M.-L. (2025) · Discover Oncology · doi:10.1007/s12672-025-04153-z
Radiogenomics predicts immune microenvironment heterogeneity and response to combination immunotherapy in hepatocellular carcinoma
Xu, Z., Liu, Y.-W., Ji, Y., Cao, S.-Y., Wang, T., Wu, H.-Y., Tang, W., Wu, X.-F., Xia, Y.-X., Xu, Q., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07627-4
Self-citation
Deep learning techniques for using computed tomography imaging for hepatocellular carcinoma diagnosis, treatment and prognosis
Chen, Y., Zhang, Q., & Zhang, M.-Y. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i5.113592
Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy
Yang, L., Yang, J., Xiong, Z., Wei, J., Jiang, X., Ye, H., & Li, Y. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01741-2
Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy
Zhong, D., Liang, Y., Su, Y., Yang, Q., Yan, H., Shi, Y., Huang, X., & Shang, J. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261421357
Pre-Treatment HBV Activation Modulates Circulating Immune Markers in Hepatocellular Carcinoma Patients Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs
Qin, L., Zhu, L., Wang, Y., Yang, H., Shen, J., & Zhu, X. (2026) · Cancer Management and Research · doi:10.2147/cmar.s563546
Transforming Histology into Virtual Multiplex Immunofluorescence to Decode Prognostic Spatial Immunity in Hepatocellular CarcinomaPreprint
Cai, L., Jiang, S., Liang, J., Liu, F., Zhang, B., Reitsam, N. G., Zeng, Q., Hu, Z., Ma, Y., Li, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.25.707931
Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances
Khorasani, S. K., Boroumandi, S., Darzi, A., Shokouhfar, M., Abdali, P., Eini, P., Vanan, A. G., & Bahrami, N. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02099-2 · Cited by 1
Spatial remodeling of the tumor immune microenvironment in hepatocellular carcinoma with cirrhosis driven by Treg-CD8⁺T cell crosstalk via the SPP1-ITGA4 axis
Xue, D., Qiu, X., Bao, M., Song, D., Lin, Y., Bao, J., Wu, J., Zhou, T., Wang, S., Yang, S., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102734
Prognostic value of nutritional-inflammatory markers in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Chen, Z., Zheng, H., Mao, Y., Chen, Z., He, P., Xu, Y., & Lu, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004203
YEATS2/TAK1 axis mediates TGF-β1 driven adaptive resistance to sorafenib in hepatocellular carcinoma
Bai, L., Wang, Y., Li, G., Song, Y., Yu, Y., & Tang, R. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153693
Prognostic Nomogram for Hepatocellular Carcinoma Patients with High Systemic Immune-Inflammation Index: Validation in Surgical and Immunotherapy Cohorts and Exploration of Immune Microenvironment Mechanisms
Wang, X., Hu, Z., Ding, J., Zheng, S., Wei, B., Zhou, Y., & Wang, S. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s588390
Self-citation
Current progress in the pathophysiology and potential therapeutic targets of acute-on-chronic liver failure through multiomics approaches
Yu, Y., Li, M., Xie, Y., Wang, F.-S., & Shi, M. (2026) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000212
Stéatopathie métabolique et carcinome hépatocellulaire : prédiction de la carcinogenèse à la réponse au traitement par profilage protéomique
Delamarre, A. (2024) · theses.fr (ABES) · doi:10.70675/ec8920bbza20cz485dzbc51zcc7223270689
CEP72 promotes malignant progression and shapes the tumor immune microenvironment in hepatocellular carcinoma: integrated multi-cohort bioinformatics and in vitro validation
Zhu, M., Wang, K., Feng, X., & Cai, Q. (2026) · Scientific Reports · doi:10.1038/s41598-026-48035-y
Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practice
Martínez-Artero, B. B., Alimenti, E., Carter, J. K., Pinato, D. J., & Villanueva, A. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101856
Self-citation
Preoperative MRI features for predicting response to postoperative adjuvant anti-PD-1 therapy in hepatocellular carcinoma
He, X., Wang, S., Ye, Z., Zhan, J., Sun, Y., Hu, S., & Peng, Z. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111853
Blockade of the CLCF1–CNTFR axis enhances the efficacy of GPC3 CAR-T cell therapy in hepatocellular carcinoma
Zhang, H. Z. H., Pan, Q., Xiang, T., Huang, L., Zhong, H., Yang, X., Li, Y., Luo, J., Chen, H., Tang, Y., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108209
Extracellular vesicles as signal hubs and targeted platforms in hepatocellular carcinoma immunotherapy
Li, J., Du, G., Liu, Q., Lv, J., Qi, W., Liu, H., Qi, H., Qiu, W., & Wang, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108241
PCBP1 suppresses autophagic degradation of STAT6 to promote M2-like TAM polarization in hepatocellular carcinoma
Luo, Y., Zhang, X., Yang, H., Yao, Y., Wu, H., Zhang, Z., Ye, D., Pan, B., Wang, X., & Tang, N. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112588
Self-citation
Resistance to immune checkpoint inhibitors in hepatocellular carcinoma: mechanisms and combination strategies to overcome it
He, T., Zhang, L., & Zhao, Q. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.74
Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis
Zhou, C., Li, H., Qian, G., Yu, W., Zheng, S., Shen, Z., & Wang, Y. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261450424
Clustering of quantitative CT features identifies HCC subtypes with distinct prognosis and immune signatures
Wu, S., Peng, F., Huang, J., Xu, L., Zhang, X., Bao, Y., & Chen, Y. (2026) · European Radiology Experimental · doi:10.1186/s41747-026-00730-1
TLCD1 correlates with malignant progression of hepatocellular carcinoma and activation of the ERK signaling cascade
Wen, P., Liu, Q., Guo, X., Tan, C., Xiaonian, Z., Li, X., Du, Y., Zhang, Q., Liu, L., & Bei, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-55516-7 · Cited by 1

Authors: Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W.
Affiliations: National Institutes of Health (US)
Tisch Cancer Institute (US)
National Cancer Institute (US)
Johns Hopkins University (US)
Corresponding author: Greten, Tim F.
ORCID: Greten, Tim F.
Villanueva, Augusto
Korangy, Firouzeh
Ruf, Benjamin
Yarchoan, Mark
Ma, Lichun
Ruppin, Eytan
Wang, Xin W.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2023-09-19
Volume: 20
Issue: 11
Pages: 780-798
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/s41571-023-00816-4
OpenAlex: W4386845699
Cited by: 227
References: 205
Citations by year: 2026: 66 · 2025: 88 · 2024: 71 · 2023: 2
FWCI: 7.38
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: hepatocellular carcinoma, immune checkpoint inhibitors, predictive biomarkers, atezolizumab plus bevacizumab, single-cell RNA sequencing, circulating tumor cells, high-dimensional flow cytometry, tumor microbiome, radiomics, gene expression signatures, spatial transcriptomics, biomarker-driven trials, immunotherapy selection
MeSH terms: Sorafenib, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers for immunotherapy of hepatocellular carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks